Loading…

An in vitro comparison of commonly used topical glucocorticoid preparations

Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinop...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 1999-09, Vol.104 (3), p.623-629
Main Authors: Stellato, Cristiana, Atsuta, Jun, Bickel, Carol A., Schleimer, Robert P.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03
cites cdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03
container_end_page 629
container_issue 3
container_start_page 623
container_title Journal of allergy and clinical immunology
container_volume 104
creator Stellato, Cristiana
Atsuta, Jun
Bickel, Carol A.
Schleimer, Robert P.
description Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B. Methods: Cells were treated for 24 hours with increasing concentrations (range 10 –13 to 10 –6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry. Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP > MF > BUD > BDP ≅ TAA >> HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP >> BUD > TAA > HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive. Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)
doi_str_mv 10.1016/S0091-6749(99)70334-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70036184</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674999703349</els_id><sourcerecordid>70036184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMozjj6CEoXIrqonlx6yUqGwRsOuFDXIZMmEmmbmrQD8_ZmLqg7Nwk_-f6cw4fQKYZrDDi_eQXgOM0Lxi85vyqAUpbyPTTGwIs0L0m2j8Y_yAgdhfAJMdOSH6IRBlaSkpZj9DxtE9smS9t7lyjXdNLb4NrEmXVqXFuvkiHoKuldZ5Wsk496UE4531vlbJV0XseK7K1rwzE6MLIO-mR3T9D7_d3b7DGdvzw8zabzVGWU9GmFs4wpyjHOK8AFAQMEFkbxEkwhi8LkWmUSaE6pIQZyHU9NFKaMccbjwwRdbP_tvPsadOhFY4PSdS1b7YYgCohlXLIIZltQeReC10Z03jbSrwQGsbYoNhbFWpHgXGwsCh57Z7sBw6LR1Z_WVlsEzneADFGK8bJVNvxynJWMkIjdbjEdbSyt9iIoq1ulK-u16kXl7D-bfAMQSo57</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70036184</pqid></control><display><type>article</type><title>An in vitro comparison of commonly used topical glucocorticoid preparations</title><source>ScienceDirect Freedom Collection</source><creator>Stellato, Cristiana ; Atsuta, Jun ; Bickel, Carol A. ; Schleimer, Robert P.</creator><creatorcontrib>Stellato, Cristiana ; Atsuta, Jun ; Bickel, Carol A. ; Schleimer, Robert P.</creatorcontrib><description>Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B. Methods: Cells were treated for 24 hours with increasing concentrations (range 10 –13 to 10 –6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry. Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP &gt; MF &gt; BUD &gt; BDP ≅ TAA &gt;&gt; HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP &gt;&gt; BUD &gt; TAA &gt; HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive. Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/S0091-6749(99)70334-9</identifier><identifier>PMID: 10482838</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Administration, Topical ; Adult ; allergy ; Anti-Inflammatory Agents - pharmacology ; basophil ; Basophils - cytology ; Basophils - drug effects ; Biological and medical sciences ; Cell Line ; Cell Survival - drug effects ; Cells, Cultured ; eosinophil ; Eosinophils - drug effects ; epithelial cells ; Glucocorticoids ; Glucocorticoids - pharmacology ; Histamine Release - drug effects ; Humans ; In Vitro Techniques ; Medical sciences ; Pharmacology. Drug treatments ; Respiratory system ; Vascular Cell Adhesion Molecule-1 - biosynthesis</subject><ispartof>Journal of allergy and clinical immunology, 1999-09, Vol.104 (3), p.623-629</ispartof><rights>1999 Mosby, Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</citedby><cites>FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1948422$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10482838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stellato, Cristiana</creatorcontrib><creatorcontrib>Atsuta, Jun</creatorcontrib><creatorcontrib>Bickel, Carol A.</creatorcontrib><creatorcontrib>Schleimer, Robert P.</creatorcontrib><title>An in vitro comparison of commonly used topical glucocorticoid preparations</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B. Methods: Cells were treated for 24 hours with increasing concentrations (range 10 –13 to 10 –6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry. Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP &gt; MF &gt; BUD &gt; BDP ≅ TAA &gt;&gt; HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP &gt;&gt; BUD &gt; TAA &gt; HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive. Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)</description><subject>Administration, Topical</subject><subject>Adult</subject><subject>allergy</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>basophil</subject><subject>Basophils - cytology</subject><subject>Basophils - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Cells, Cultured</subject><subject>eosinophil</subject><subject>Eosinophils - drug effects</subject><subject>epithelial cells</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - pharmacology</subject><subject>Histamine Release - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>Vascular Cell Adhesion Molecule-1 - biosynthesis</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKxDAUhoMozjj6CEoXIrqonlx6yUqGwRsOuFDXIZMmEmmbmrQD8_ZmLqg7Nwk_-f6cw4fQKYZrDDi_eQXgOM0Lxi85vyqAUpbyPTTGwIs0L0m2j8Y_yAgdhfAJMdOSH6IRBlaSkpZj9DxtE9smS9t7lyjXdNLb4NrEmXVqXFuvkiHoKuldZ5Wsk496UE4531vlbJV0XseK7K1rwzE6MLIO-mR3T9D7_d3b7DGdvzw8zabzVGWU9GmFs4wpyjHOK8AFAQMEFkbxEkwhi8LkWmUSaE6pIQZyHU9NFKaMccbjwwRdbP_tvPsadOhFY4PSdS1b7YYgCohlXLIIZltQeReC10Z03jbSrwQGsbYoNhbFWpHgXGwsCh57Z7sBw6LR1Z_WVlsEzneADFGK8bJVNvxynJWMkIjdbjEdbSyt9iIoq1ulK-u16kXl7D-bfAMQSo57</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>Stellato, Cristiana</creator><creator>Atsuta, Jun</creator><creator>Bickel, Carol A.</creator><creator>Schleimer, Robert P.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990901</creationdate><title>An in vitro comparison of commonly used topical glucocorticoid preparations</title><author>Stellato, Cristiana ; Atsuta, Jun ; Bickel, Carol A. ; Schleimer, Robert P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Administration, Topical</topic><topic>Adult</topic><topic>allergy</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>basophil</topic><topic>Basophils - cytology</topic><topic>Basophils - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Cells, Cultured</topic><topic>eosinophil</topic><topic>Eosinophils - drug effects</topic><topic>epithelial cells</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - pharmacology</topic><topic>Histamine Release - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>Vascular Cell Adhesion Molecule-1 - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stellato, Cristiana</creatorcontrib><creatorcontrib>Atsuta, Jun</creatorcontrib><creatorcontrib>Bickel, Carol A.</creatorcontrib><creatorcontrib>Schleimer, Robert P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stellato, Cristiana</au><au>Atsuta, Jun</au><au>Bickel, Carol A.</au><au>Schleimer, Robert P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An in vitro comparison of commonly used topical glucocorticoid preparations</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>104</volume><issue>3</issue><spage>623</spage><epage>629</epage><pages>623-629</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>Background: Glucocorticoids (GC) are potent inhibitors of peripheral blood eosinophil, basophil, and airway epithelial cell function. Objectives: We compared in vitro the inhibitory activity of synthetic GC used for topical treatment in asthma and rhinitis on basophil histamine release (HR), eosinophil viability, and expression of vascular cell adhesion molecule-1 (VCAM-1) in the human bronchial epithelial cell line BEAS-2B. Methods: Cells were treated for 24 hours with increasing concentrations (range 10 –13 to 10 –6 mol/L) of fluticasone propionate (FP), mometasone furoate (MF), budesonide (BUD), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), hydrocortisone (HC), or dimethyl sulfoxide diluent before challenge. HR was measured by a fluorometric assay, viability of purified eosinophils was assessed by erythrosin B dye exclusion, and expression of VCAM-1 was measured by flow cytometry. Results: GC induced a concentration-dependent inhibition of anti-IgE-induced HR. Maximum inhibition ranged from 59.7% to 81%, with a rank order of GC potency of FP &gt; MF &gt; BUD &gt; BDP ≅ TAA &gt;&gt; HC. Three-day treatment of eosinophils with GC concentration-dependently inhibited IL-5–induced eosinophil viability, with a rank of potency almost identical to that observed with basophil HR. The rank order of potency of GC for inhibition of the expression of VCAM-1 in BEAS-2B cells was MF ≅ FP &gt;&gt; BUD &gt; TAA &gt; HC ≅ BDP. Inhibitory concentration of 50% values revealed that epithelial cells were the most sensitive and eosinophils were the least sensitive. Conclusions: These data, combined with information on pharmacodynamics of these drugs in vivo, may be useful in estimating GC local anti-inflammatory effects. (J Allergy Clin Immunol 1999;104:623-9.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>10482838</pmid><doi>10.1016/S0091-6749(99)70334-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-6749
ispartof Journal of allergy and clinical immunology, 1999-09, Vol.104 (3), p.623-629
issn 0091-6749
1097-6825
language eng
recordid cdi_proquest_miscellaneous_70036184
source ScienceDirect Freedom Collection
subjects Administration, Topical
Adult
allergy
Anti-Inflammatory Agents - pharmacology
basophil
Basophils - cytology
Basophils - drug effects
Biological and medical sciences
Cell Line
Cell Survival - drug effects
Cells, Cultured
eosinophil
Eosinophils - drug effects
epithelial cells
Glucocorticoids
Glucocorticoids - pharmacology
Histamine Release - drug effects
Humans
In Vitro Techniques
Medical sciences
Pharmacology. Drug treatments
Respiratory system
Vascular Cell Adhesion Molecule-1 - biosynthesis
title An in vitro comparison of commonly used topical glucocorticoid preparations
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A29%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20in%20vitro%20comparison%20of%20commonly%20used%20topical%20glucocorticoid%20preparations&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Stellato,%20Cristiana&rft.date=1999-09-01&rft.volume=104&rft.issue=3&rft.spage=623&rft.epage=629&rft.pages=623-629&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/S0091-6749(99)70334-9&rft_dat=%3Cproquest_cross%3E70036184%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c532t-d1554c39116d01720f020bfc980f7a77f6ec5a03633f2f06ef2fe2c1344949a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70036184&rft_id=info:pmid/10482838&rfr_iscdi=true